Program
hyaluronidase (human recombinant)
Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.
Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| argenx | 2211 open or running | phase 4since Oct 7, 2024 | Feb 20, 2020 | Mar 2027phase 2 · NCT06655155 |
| Halozyme Therapeutics | 200 open or running | phase 4since Apr 4, 2006 | Apr 4, 2006 | none ahead |
| Takeda | 60 open or running | phase 3since Dec 23, 2008 | Oct 29, 2008 | none ahead |
| Hoffmann-La Roche | 42 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | Aug 31, 2029phase 2 · NCT07503340 |
| Baxter Healthcare | 30 open or running | phase 4since Dec 10, 2008 | Dec 10, 2008 | none ahead |
| Fosun Pharma | 11 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Aug 6, 2015 | Aug 6, 2015 | none ahead |
Also a collaborator on its studies: BioLineRx.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Apr 4, 2006.
- Aug 14, 2024Phase 3 study in Myasthenia Gravisargenx · NCT06558279 · 141 enrolled · United States, Australia, Austria and more
- Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT06637072 · 23 enrolled · United States
- Oct 22, 2024Phase 2 study in Scleroderma, Systemicargenx · NCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
- Nov 10, 2024Phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847 · 631 enrolled · United States, Argentina, Australia and more
- Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)argenx · NCT06909214 · 30 planned · United States
- Feb 24, 2026Fosun Pharma’s first study: phase 1 study in Healthy Adult MaleNew to Fosun PharmaFosun Pharma · NCT07484893 · 24 planned · China
- Mar 25, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT07503340 · 25 planned
- Apr 30, 2026Phase 3 study in Graves Diseaseargenx · NCT07570316 · 230 planned · United States, Georgia, United Kingdom
- May 13, 2026Phase 3 study in Graves Diseaseargenx · NCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
- Jun 18, 2026Phase 1 study in Multiple SclerosisHoffmann-La Roche · NCT07667322 · 75 enrolled · United States, Brazil, Mexico and more
- Jul 29, 2026Phase 2 study in Sjogrens Diseaseargenx · NCT07760818 · 75 planned
- Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
- Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798
- Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925
Ahead
- Mar 2027Primary completion: phase 2 study in Scleroderma, Systemicargenx · NCT06655155
- Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT04280718
- Jul 2027Primary completion: phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847
- Sep 2027Primary completion: phase 3 study in Myasthenia Gravisargenx · NCT06392386
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 57 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07760818Sjogrens Disease | 2 | Not yet recruiting | argenx | Jul 28, 2028 | 75 |
| NCT07667322Multiple Sclerosis · United States, Brazil, Mexico and more | 1 | Active, not recruiting | Hoffmann-La Roche | Sep 1, 2026 | 75 |
| NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more | 3 | Recruiting | argenx | Jun 2028 | 230 |
| NCT07570316Graves Disease · United States, Georgia, United Kingdom | 3 | Recruiting | argenx | Jun 2028 | 230 |
| NCT07503340Multiple Sclerosis, Relapsing-Remitting | 2 | Not yet recruiting | Hoffmann-La Roche | Aug 31, 2029 | 25 |
| NCT07484893Healthy Adult Male · China | 1 | Not yet recruiting | Fosun Pharma | Aug 25, 2026 | 24 |
| NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States | 4 | Recruiting | argenx | Aug 2026 | 30 |
| NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | argenx | Jul 2027 | 631 |
| NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more | 2 | Active, not recruiting | argenx | Mar 2027 | 87 |
| NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States | 4 | Completed | argenx | Feb 19, 2026 | 23 |
| NCT06558279Myasthenia Gravis · United States, Australia, Austria and more | 3 | Active, not recruiting | argenx | Jan 12, 2026 | 141 |
| NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | argenx | Sep 2027 | 12 |
| NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more | 3 | Terminated | argenx | Dec 15, 2025 | 105 |
| NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more | 3 | Terminated | argenx | Dec 15, 2025 | 102 |
| NCT05979441Myositis · United States, Argentina, Austria and more | 3 | By invitation | argenx | Sep 2028 | 240 |
| NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Terminated | argenx | Mar 20, 2025 | 64 |
| NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more | 3 | Completed | argenx | Sep 13, 2024 | 98 |
| NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | argenx | Oct 2027 | 173 |
| NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more | 3 | Completed | argenx | Dec 31, 2024 | 184 |
| NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more | 3 | Completed | argenx | Nov 2, 2021 | 110 |
| NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Completed | argenx | Oct 9, 2023 | 207 |
| NCT04598477Pemphigus · United States, Australia, Bulgaria and more | 3 | Terminated | argenx | Mar 25, 2024 | 183 |
| NCT04598451Pemphigus · United States, Australia, Bulgaria and more | 3 | Completed | argenx | Aug 22, 2023 | 222 |
| NCT04564066Healthy Volunteers · Netherlands | 1 | Completed | argenx | Dec 24, 2020 | 54 |
| NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more | 2 | Active, not recruiting | argenx | Apr 30, 2027 | 229 |
| NCT04045028Multiple Myeloma · United States, Korea, Republic of | 1 | Terminated | Hoffmann-La Roche | Mar 28, 2023 | 41 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT02519452Multiple Myeloma · United States, Denmark, France and more | 1 | Completed | Johnson & Johnson | Dec 13, 2017 | 120 |
| NCT01848990Diabetes Mellitus, Type 1 · United States | 4 | Completed | Halozyme Therapeutics | Feb 2014 | 456 |
| NCT01756157Angioedemas, Hereditary · United States, Germany, Spain and more | 2 | Completed | Takeda | Sep 13, 2013 | 47 |
| NCT01572012Healthy · United States | 1 | Completed | Halozyme Therapeutics | Nov 2013 | 12 |
| NCT01526733Diabetes Mellitus, Type 1 · United States | 4 | Completed | Halozyme Therapeutics | Aug 2012 | 25 |
| NCT01485796Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Jan 1, 2013 | 54 |
| NCT01426763Angioedemas, Hereditary · United States | 2 | Completed | Takeda | Nov 28, 2011 | 12 |
| NCT01275131Diabetes Mellitus, Type 1 · United States | 1 | Completed | Halozyme Therapeutics | Dec 2011 | 45 |
| NCT01194258Diabetes Mellitus, Type 2 · United States | 2 | Completed | Halozyme Therapeutics | Aug 2011 | 132 |
| NCT01194245Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Aug 2011 | 135 |
| NCT01175213Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Aug 6, 2013 | 66 |
| NCT01120431Dehydration | 4 | Withdrawn | Baxter Healthcare | May 2010 | 0 |
| NCT01116102Dehydration · United States | 4 | Terminated | Baxter Healthcare | May 2010 | 20 |
| NCT00979875Insulin Resistance · United States | 1 | Completed | Halozyme Therapeutics | Feb 2010 | 14 |
| NCT00928447Dermatitis, Allergic Contact · United States | 2 | Completed | Halozyme Therapeutics | Sep 13, 2009 | 22 |
| NCT00916357Diabetes Mellitus, Type 2 · United States | 2 | Completed | Halozyme Therapeutics | Nov 2009 | 23 |
| NCT00883558Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Feb 2010 | 48 |
| NCT00862849Diabetes Mellitus · United States | 1 | Completed | Halozyme Therapeutics | Jun 2009 | 22 |
| NCT00814320Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | Takeda | Nov 11, 2010 | 89 |
| NCT00807963Risk Factors for or a Diagnosis of Osteoporosis · United States | 1 | Completed | Halozyme Therapeutics | Sep 21, 2009 | 31 |
| NCT00807885Dehydration · United States | 4 | Completed | Baxter Healthcare | Jan 2009 | 100 |
| NCT00782587Non-Muscle Invasive Bladder Neoplasms · United States | 1 | Completed | Halozyme Therapeutics | Mar 2009 | 14 |
| NCT00782106Primary Immunodeficiency Diseases · United States | 2 | Completed | Takeda | Nov 1, 2007 | 11 |
| NCT00774800Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Mar 2009 | 22 |
| NCT00773175Dehydration · United States | 4 | Completed | Halozyme Therapeutics | Nov 2009 | 148 |
| NCT00656370Healthy · United States | 4 | Completed | Halozyme Therapeutics | Jan 30, 2008 | 15 |
| NCT00593281Pain · United States | 3 | Completed | Halozyme Therapeutics | Oct 2006 | 13 |
| NCT00435604Healthy | 1 | Completed | Halozyme Therapeutics | 15 | |
| NCT00318643Urinary Bladder Neoplasms · United States | 2 | Completed | Halozyme Therapeutics | Aug 11, 2009 | 27 |
| NCT00311519Healthy · United States | 4 | Completed | Halozyme Therapeutics | 50 |
How it is read
Names in the registry
- “Efgartigimod PH20 SC”, 12 entries
- “efgartigimod PH20 SC”, 10 entries
- “rHuPH20”, 5 entries
- “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
- “recombinant human hyaluronidase”, 3 entries
Codes read as this program: RHUPH20.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 6 studies
- Myasthenia Gravis, 5 studies
- Primary Immunodeficiency Diseases, 4 studies
- Dehydration, 4 studies
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.